CGPHF (Grand Pharmaceutical Group) Asset Turnover: 0.23 (As of Dec. 2025)


What is Grand Pharmaceutical Group Asset Turnover?

Grand Pharmaceutical Group CGPHF 87 Asset Turnover is 0.23 as of Dec. 2025. GuruFocus rates CGPHF with a GF Score™ of 87/100. The stock has 6 warning signs investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Grand Pharmaceutical Group's Revenue for the six months ended in Dec. 2025 was $793.74 Mil. Grand Pharmaceutical Group's Total Assets for the quarter that ended in Dec. 2025 was $3,431.88 Mil. Therefore, Grand Pharmaceutical Group's Asset Turnover for the quarter that ended in Dec. 2025 was 0.23.

Asset Turnover is linked to ROE % through Du Pont Formula. Grand Pharmaceutical Group's annualized ROE % for the quarter that ended in Dec. 2025 was 0.84%. It is also linked to ROA % through Du Pont Formula. Grand Pharmaceutical Group's annualized ROA % for the quarter that ended in Dec. 2025 was 0.54%.


Grand Pharmaceutical Group  (OTCPK:CGPHF) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Grand Pharmaceutical Group's annulized ROE % for the quarter that ended in Dec. 2025 is

ROE %**(Q: Dec. 2025 )
=Net Income/Total Stockholders Equity
=18.47/2186.3235
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(18.47 / 1587.484)*(1587.484 / 3431.883)*(3431.883/ 2186.3235)
=Net Margin %*Asset Turnover*Equity Multiplier
=1.16 %*0.4626*1.5697
=ROA %*Equity Multiplier
=0.54 %*1.5697
=0.84 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Grand Pharmaceutical Group's annulized ROA % for the quarter that ended in Dec. 2025 is

ROA %(Q: Dec. 2025 )
=Net Income/Total Assets
=18.47/3431.883
=(Net Income / Revenue)*(Revenue / Total Assets)
=(18.47 / 1587.484)*(1587.484 / 3431.883)
=Net Margin %*Asset Turnover
=1.16 %*0.4626
=0.54 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Grand Pharmaceutical Group Asset Turnover Related Terms


Grand Pharmaceutical Group Asset Turnover Historical Data

* Premium members only.

The historical data trend for Grand Pharmaceutical Group's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grand Pharmaceutical Group Asset Turnover Chart

Grand Pharmaceutical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.45 0.44 0.47 0.49 0.47

Grand Pharmaceutical Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.26 0.23 0.24 0.23

CGPHF vs ZTS: Asset Turnover Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grand Pharmaceutical Group Asset Turnover vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Grand Pharmaceutical Group's Asset Turnover falls into.



Grand Pharmaceutical Group Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Grand Pharmaceutical Group's Asset Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=1578.664/( (3214.959+3491.518)/ 2 )
=1578.664/3353.2385
=0.47

Grand Pharmaceutical Group's Asset Turnover for the quarter that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=793.742/( (3372.248+3491.518)/ 2 )
=793.742/3431.883
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.23 mean?
Grand Pharmaceutical Group (CGPHF) has a Asset Turnover of 0.23 as of Dec. 2025. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Grand Pharmaceutical Group and its competitors.
Is Grand Pharmaceutical Group's Asset Turnover too high?
Grand Pharmaceutical Group's current Asset Turnover is 0.23. Overall, Grand Pharmaceutical Group has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Grand Pharmaceutical Group's Asset Turnover compare to ZTS?
Grand Pharmaceutical Group's Asset Turnover of 0.23 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Drug Manufacturers company?
A good Asset Turnover depends on the Drug Manufacturers industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Grand Pharmaceutical Group and its competitors. Grand Pharmaceutical Group's current Asset Turnover is 0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Pharmaceutical Group stock overvalued right now?
Grand Pharmaceutical Group (CGPHF) has a current Asset Turnover of 0.23. The current Asset Turnover is 0.23. Grand Pharmaceutical Group's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Grand Pharmaceutical Group (CGPHF), the current Asset Turnover is 0.23 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Grand Pharmaceutical Group Business Description

Other Exchanges 00512:Hong KongMX6A:Germany
Address 99 Queen\'s Road Central, Units 3302, 33rd Floor, The Center, Hong Kong, HKG
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.